Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AHCY | P23526 | 4/20 | 0.34 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.34 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.33 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.33 |
| ▸ | PI4KA | P42356 | 1/20 | 0.33 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.33 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.33 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.33 |
| ▸ | ADA | P00813 | 2/20 | 0.32 |
| ▸ | PDE2A | O00408 | 1/20 | 0.32 |
| ▸ | PDE4A | P27815 | 1/20 | 0.32 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.32 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.32 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6904115 | 0.90 | AHCY (0.33) | AHCYADORA2AADORA2BADORA1PI4KA | |
| SCHEMBL6697105 | 0.90 | AHCY (0.36) | AHCYADORA2AADORA2BADORA1PI4KA | |
| SCHEMBL6903285 | 0.81 | HPRT1 (0.45) | AHCY | |
| SCHEMBL6904695 | 0.81 | FGFR1 (0.42) | AHCY | |
| SCHEMBL29782858 | 0.78 | FDPS (0.47) | AHCYADORA2AADORA2BADORA1PI4KA | |
| SCHEMBL6693460 | 0.78 | AHCY (0.37) | AHCYADORA2AADORA2BADORA1PI4KA | |
| SCHEMBL6903378 | 0.75 | CYP1A2 (0.51) | — | |
| SCHEMBL5080086 | 0.72 | ADORA2A (0.59) | AHCYADORA2AADORA2BADORA1PI4KA | |
| SCHEMBL6055498 | 0.70 | CDK1 (0.43) | — | |
| SCHEMBL15426097 | 0.69 | CCNB2 (0.42) | ADORA2AADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2004106350-A1 | NUCLEOSIDE ANALOGS AS VIRAL POLYMERASE INHIBITORS | BIOCRYST PHARMACEUTICAL, INC. (US) | 2004-12-09 | — | — | WO | claimed |
| US-20040014722-A1 | Nucleosides, preparation thereof and use as inhibitors of RNA viral polymerases | BIOCRYST PHARMACEUTICALS, INC. | 2004-01-22 | — | — | US | claimed |
| WO-2004106350-A1 | NUCLEOSIDE ANALOGS AS VIRAL POLYMERASE INHIBITORS | BIOCRYST PHARMACEUTICAL, INC. (US) | 2004-12-09 | — | — | WO | disclosed |
| US-20040014722-A1 | Nucleosides, preparation thereof and use as inhibitors of RNA viral polymerases | BIOCRYST PHARMACEUTICALS, INC. | 2004-01-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040014722-A1 | Nucleosides, preparation thereof and use as inhibitors of RNA viral polymerases | NSUN2, POLR2H, NSUN3 | AHCY 921/4885ADORA2A 2690/4885ADORA2B 1705/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.